CRISPR assisted Lipid Nanoparticle (LNP) Formulation Service
Lipid nanoparticles (LNPs) are advanced nanoscale delivery systems composed of biocompatible lipids, widely recognized for their high encapsulation efficiency, excellent biocompatibility, and ability to protect and transport genetic material across cellular membranes. These properties make LNPs a preferred vehicle for delivering CRISPR components, ensuring efficient gene editing with minimal off-target effects. At Creative Biolabs, our expert team provides customized LNP design and formulation solutions tailored to meet diverse therapeutic and research needs, enabling clients to accelerate the development of gene therapies with enhanced precision and delivery efficiency.
Why LNPs Are Valuable for CRISPR Delivery?
Non-Viral Delivery with Flexible Payload Capacity
Viral vectors remain important tools in gene delivery, but they may not be the best fit for every CRISPR application LNPs can be adapted to deliver different CRISPR payload formats. For projects requiring transient editing, Cas mRNA and sgRNA co-delivery can be formulated into LNPs to allow temporary intracellular expression of nuclease proteins. For direct editing machinery delivery, RNP-loaded LNPs may help shorten intracellular activity windows. For complex editing systems such as base editing or prime editing, customized LNP formulation may support larger mRNA payloads and guide components. This flexibility allows researchers to select the CRISPR format that best suits their editing strategy.
Protection of Sensitive CRISPR Components
CRISPR payloads are often vulnerable to degradation, aggregation, oxidation, hydrolysis, and loss of activity during preparation, storage, and biological delivery. RNA molecules are particularly sensitive to nuclease-mediated degradation, while protein-containing systems such as RNPs require conditions that preserve folding, complex stability, and enzymatic function. LNPs provide a protective microenvironment that shields nucleic acids and other CRISPR components from extracellular degradation and improves their chances of reaching intracellular targets.
Co-Delivery Formulation for CRISPR Systems
Many CRISPR applications require delivery of more than one component. For example, Cas9 mRNA must often be delivered together with sgRNA. Base editing systems may require editor mRNA and guide RNA. Prime editing may involve prime editor mRNA, pegRNA, and nicking sgRNA. Homology-directed repair workflows may require nuclease components and donor templates.
LNP: The "Gold Standard" of Non-Viral Delivery
Figure 1. Composition and models of mRNA lipid nanoparticles: (a) Chemical structure of representative lipids used for delivery of therapeutic nucleic acids. (b) Multilamellar vesicle (onion-like). (c) Particle with a nanostructured core. (d) Homogeneous core–shell structure.1
- Transient "Hit-and-Run" Editing: LNPs deliver mRNA or Ribonucleoprotein (RNP) complexes that achieve rapid, peak expression followed by swift degradation. This transient burst of editing machinery completes the target modification and disappears, reducing off-target cleavage to near-background levels.
- Unrestricted Payload Capacity: Unlike viral capsids, LNPs are not confined by rigid geometric constraints, allowing for the encapsulation of massive mRNA transcripts, large plasmid DNA, or bulky multiplexed RNP complexes.
- Low Immunogenicity: Formulated with biocompatible, biodegradable lipids, LNPs do not elicit the strong neutralizing antibody responses seen with viral capsids, paving the way for safe, repeated systemic administration.
Introduction of CRISPR based Lipid Nanoparticle (LNP) Formulation Service
CRISPR-based lipid nanoparticle (LNP) formulation is a next-generation delivery platform that integrates the precision of CRISPR-Cas gene editing with the efficiency of lipid-based nanocarriers. LNPs serve as versatile nanoscale vectors, capable of encapsulating various CRISPR components—such as Cas9 mRNA, guide RNAs (gRNAs), plasmids, and RNP complexes—while protecting them from degradation and ensuring precise release into target cells. Compared with conventional methods like viral vectors and electroporation, LNPs offer a safer, non-viral alternative with low immunogenicity, high delivery efficiency, and strong biocompatibility. Their tunable size, composition, and surface characteristics enable targeted or systemic delivery, making them highly adaptable across a range of applications. This technology has broad applications in gene therapy, in vivo genome editing, and disease modeling. By efficiently delivering CRISPR elements, LNPs are driving advances in the treatment of cancer, genetic disorders, infectious diseases, and more.
| Services | Description | Typical Applications |
|---|---|---|
| Feasibility Assessment | Evaluation of payload type, project goals, delivery route, and formulation requirements | Early project planning, payload compatibility review |
| Custom LNP Formulation | Design and preparation of LNPs for CRISPR payload delivery | Cas mRNA/sgRNA delivery, RNP delivery, plasmid delivery |
| Formulation Screening | Comparison of multiple lipid compositions and preparation parameters | Optimization of editing efficiency and cell compatibility |
| Co-Delivery Optimization | Development of LNPs for multi-component CRISPR systems | Cas9 mRNA + sgRNA, base editor + gRNA, prime editor systems |
| In Vitro Delivery Support | Preparation of LNPs for cell-based editing experiments | Cell line editing, primary cell editing, disease model generation |
| In Vivo-Oriented LNP Preparation | Formulation support for animal study delivery requirements | Preclinical proof-of-concept, tissue-targeted editing studies |
| Analytical Characterization | Evaluation of particle size, PDI, zeta potential, encapsulation efficiency, and stability | QC release, batch comparison, formulation selection |
| Project-Specific Optimization | Customized troubleshooting and performance improvement | Low editing efficiency, poor stability, high toxicity, variable results |
Workflow of CRISPR based Lipid Nanoparticle (LNP) Formulation Service
Figure. 2 Workflow of our CRISPR based Lipid Nanoparticle (LNP) Formulation Service.
Why Choose Creative Biolabs?
| Capability | How It Supports Your Project |
|---|---|
| Integrated Gene Therapy Expertise | Creative Biolabs combines experience in gene delivery, CRISPR systems, nucleic acid technologies, and preclinical research support. |
| Customized Formulation Strategy | Each LNP formulation is designed according to payload type, editing goal, target cell or tissue, and downstream application. |
| Broad CRISPR Payload Support | We support Cas mRNA, sgRNA, RNP, plasmid DNA, base editor components, prime editor systems, and co-delivery formats. |
| Strong Analytical Characterization | Particle size, PDI, zeta potential, encapsulation efficiency, and other QC data help ensure formulation reliability. |
| Flexible Project Scale | Services can be adapted for early feasibility studies, formulation screening, in vitro research, and in vivo-oriented projects. |
| Troubleshooting-Oriented Support | Our team helps identify and address issues such as low encapsulation, poor editing efficiency, cytotoxicity, and instability. |
| One-Stop CRISPR Service Integration | LNP formulation can be combined with gRNA design, vector construction, donor design, editing assays, and disease model development. |
| Client-Focused Delivery | We provide practical deliverables, clear communication, and project-specific recommendations to accelerate research progress. |
Our Collaboration Process
-
Step 1 Initial Discussion
Clients begin by sharing project goals, CRISPR payload details, target cells or tissues, and desired downstream applications. Our team reviews the information and recommends an appropriate formulation strategy.
-
Step 2 Technical Proposal
Creative Biolabs prepares a customized project plan covering formulation design, preparation scale, characterization methods, optional optimization steps, timeline, and deliverables.
-
Step 3 Formulation Development
Our scientists prepare LNP formulations according to the agreed plan. Depending on the project scope, this may include single-batch preparation, formulation screening, or iterative optimization.
-
Step 4 QC and Data Review
Prepared formulations undergo analytical characterization. Results are reviewed to determine whether the formulation meets project requirements or whether additional optimization is recommended.
-
Step 5 Delivery and Follow-Up
Final LNP formulations and project documentation are delivered to the client. Our team remains available for follow-up discussion, troubleshooting, and planning of subsequent studies.
Customer Reviews
Frequently Asked Questions (FAQ)
Q: What are the typical encapsulation efficiencies and particle sizes I can expect for a standard mRNA/sgRNA LNP formulation?
A: With our heavily optimized lipid libraries and microfluidic protocols, we routinely and stably achieve Encapsulation Efficiencies (EE%) exceeding 85%, and frequently >90%. Particle size distributions are tightly controlled and highly reproducible, falling within the ideal 60 nm to 100 nm range with a Polydispersity Index (PDI) strictly < 0.2.
Q: Delivering a Cas9 Ribonucleoprotein (RNP) complex is vastly different from delivering mRNA. Do you possess the specific capabilities to encapsulate proteins?
A: Yes. RNP encapsulation is significantly more challenging due to the uneven charge distribution, complex topography, and generally lower isoelectric points of proteins compared to the uniform negative charge of nucleic acid backbones. Standard lipid mixes will fail. Creative Biolabs has developed highly specialized, proprietary formulation buffers, modified surface-charge lipids, and hybrid polymer strategies specifically engineered to trap RNP complexes within the LNP core without denaturing the Cas9 nuclease, resulting in highly potent in vitro and in vivo editing.
Q: My therapeutic strategy requires editing in extrahepatic tissues (e.g., the lungs or the spleen). Can your LNPs bypass the liver?
A: Absolutely. While conventional LNPs naturally accumulate in the liver due to ApoE-mediated uptake, we employ advanced formulation engineering to alter this tropism. By utilizing specialized SORT (Selective Organ Targeting) lipid technologies, adjusting the global surface charge of the nanoparticle, or incorporating active targeting ligands (like specialized antibodies or peptides) onto the PEGylated surface, we can rationally redirect the biodistribution profile to significantly enhance delivery to pulmonary, splenic, or other extrahepatic tissues.
Q: Are your custom LNPs stable for long-term storage, and do you offer lyophilization services?
A: Standard LNPs in aqueous buffers generally require storage at -70°C to -80°C to prevent particle aggregation and payload degradation. However, we offer advanced formulation stabilization services, including the strategic integration of specific cryoprotectants (such as sucrose or trehalose at optimized molarities). We also provide specialized lyophilization (freeze-drying) process development, allowing the LNPs to be converted into a stable powder format that can be easily reconstituted prior to administration, significantly simplifying cold-chain logistics.
Q: What biological materials do I need to provide to initiate a custom formulation project?
A: To commence formulation, we simply require the details of your gene editing strategy, the specific nucleic acid sequences or protein payloads (which we can also synthesize in-house on your behalf if required), and information regarding your target cell line or intended animal model. Our project managers will guide you through the rest.
How CRISPR based Lipid Nanoparticle (LNP) Formulation Service Can Assist Your Project
At Creative Biolabs, our CRISPR-based LNP Formulation Service is designed to meet the precise requirements of your research. We tailor each formulation to match your specific CRISPR payload ensuring optimal delivery efficiency and biological activity. Every batch undergoes rigorous quality control, including detailed analysis of particle size distribution, zeta potential, polydispersity index (PDI), and encapsulation efficiency, to guarantee consistency and performance. We also offer custom aliquoting for better storage, adapting to your workflow needs and experimental timelines. Whether you're working on gene therapy development, in vivo gene editing, or functional studies, our LNPs can significantly enhance delivery efficiency, reduce variability, and improve the reproducibility of your results.
Let Creative Biolabs help you accelerate your research with high-quality, custom-formulated CRISPR delivery systems. Contact us to discuss your project needs and explore tailored solutions.
Reference
- Liu Y, Huang Y, He G, et al. Development of mRNA lipid nanoparticles: targeting and therapeutic aspects. International journal of molecular sciences, 2024, 25(18): 10166. https://doi.org/10.3390/ijms251810166 Distributed under Open Access license CC BY 4.0, without modification.
